Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers [clinicaltrials:NCT02245269]

Bio2RDF uri

Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers [clinicaltrials:NCT02245269]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT02245269

Bio2RDF identifier

NCT02245269

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02245269

http://www.w3.org/2001/XMLSchema#string

brief summary [clinicaltrials_vocabulary:brief-summary]

Study to determine the ...... harmacokinetics of tipranavir

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Pharmacokinetics of Atorvastat ...... itonavir in Healthy Volunteers

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:7d7a7520a0175478c926e1a86386ced0]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:898146197051dd69912c0dbbc202d4c3]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:c035119ac4be9213418b67a3826b7a31]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:ee6f17fc5223177847f4219ad6c21822]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:1fa426539a58507aa204b8d65cb43797]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:3e63436d813d7306801c0ce583028cf2]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:6b1864d418eb1b579558acb673d4f7c8]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:7feddea2a84f4842ae785b2b91360e71]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:81c6361982bc53191c8e034b4928b077]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:e257a01a1bcf6484ffe2980bafd22b91]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:eb67bd3a72e76c642e4c4e8fe9303840]

Area under the plasma drug concentration-time curve from time zero to infinity of the analyte (AUC0-∞) up to day 22 [clinicaltrials_resource:f2c40a3e5acda4e1ff164b6ff37b65ce]

condition [clinicaltrials_vocabulary:condition]

Healthy [clinicaltrials_resource:396d45b57c2fbe3318e7b93272a2686b]

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02245269 [clinicaltrials_resource:aa31dc7eaff4ab515565f3637f911032]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Ritonavir [clinicaltrials_resource:190fd1aea09c699a89d06f1ad59f729c]

Maalox [clinicaltrials_resource:1c6d7c54a5b7e32ae53832710edd92f5]

Tipranavir [clinicaltrials_resource:c3f32648e916f11e005cc485bca21ec4]

Atorvastatin [clinicaltrials_resource:e21a2b0f6b7c7587846cffe536288261]

intervention browse [clinicaltrials_vocabulary:intervention-browse]

Tipranavir [clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f]

Antacids [clinicaltrials_resource:3802edc3d360d3c0c648acd6dfc85132]

Atorvastatin [clinicaltrials_resource:58b9fa08b4853c298624b7be6020faeb]

Ritonavir [clinicaltrials_resource:7dc4e4f837ab8fba1b64636daa50e0d3]

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-09-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

link [clinicaltrials_vocabulary:link]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02245269

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Two-way Pharmacokinetic Inte ...... g/200mg) in Healthy Volunteers

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

1.1822099609375e+3

http://www.w3.org/2001/XMLSchema#float

overall status [clinicaltrials_vocabulary:overall-status]

Completed [clinicaltrials_resource:07ca5050e697392c9ed47e6453f1453f]

oversight [clinicaltrials_vocabulary:oversight]

Canada: Public Health Agency of Canada [clinicaltrials_resource:9e4bfe7ed74f2d11c47fd43ac100de20]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2003-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

Boehringer Ingelheim [clinicaltrials_resource:5d012cfae6e8b67d8437e7145ea9a68f]

start date [clinicaltrials_vocabulary:start-date]

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02245269 study design [clinicaltrials_resource:966b83f0f963471749529463453529b1]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02245269

verification date [clinicaltrials_vocabulary:verification-date]

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02245269

http://www.w3.org/2001/XMLSchema#string

title

Pharmacokinetics of Atorvastat ...... itonavir in Healthy Volunteers

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Pharmacokinetics of Atorvastat ...... s [clinicaltrials:NCT02245269]

@en